Evidence map›Paper›PMID 41114360›Full record

ArticleFrontiers in oncology2025

Calendar time trends in synchronous metastatic urinary bladder cancer before and after the introduction of immune checkpoint inhibitors: a nation-wide population-based cohort study.

Karin Söderkvist, Christel Häggström, Oskar Hagberg, Firas Aljabery, Truls Gårdmark, Lars Holmberg, Abolfazl Hosseini, Tomas Jerlström, Henrik Kjölhede, Per-Uno Malmström and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karin SöderkvistDepartment of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
Christel HäggströmDepartment of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
Oskar HagbergDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Firas AljaberyDepartment of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.
Truls GårdmarkDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
Lars HolmbergDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Abolfazl HosseiniDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Tomas JerlströmDepartment of Urology, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Henrik KjölhedeDepartment of Urology, Sahlgrenska University Hospital and Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Per-Uno MalmströmDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Amir SherifDepartment of Diagnostics and Intervention, Urology, Umeå University, Umeå, Sweden.
Fredrik LiedbergDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Anders UllénDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

checkpoint inhibitors (ICIs)metastatic diseasepopulation based studysurvival trendsurinary bladder cancer

Identifiers

PMID41114360
PMCPMC12527856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.